ITGB3 | Integrin, beta 3 (platelet glycoprotein IIIa, antigen CD61) | Cancer-related genes CD markers Disease related genes FDA approved drug targets Plasma proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
LHCGR | Luteinizing hormone/choriogonadotropin receptor | Disease related genes FDA approved drug targets G-protein coupled receptors Predicted intracellular proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
M6PR | Mannose-6-phosphate receptor (cation dependent) | FDA approved drug targets Predicted intracellular proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Expressed in all |
MPL | MPL proto-oncogene, thrombopoietin receptor | Cancer-related genes CD markers Disease related genes FDA approved drug targets Predicted membrane proteins
| | | | | Not detected |
MS4A1 | Membrane-spanning 4-domains, subfamily A, member 1 | CD markers Disease related genes FDA approved drug targets Predicted intracellular proteins Predicted membrane proteins Transporters
| | | | | Group enriched |
MS4A2 | Membrane-spanning 4-domains, subfamily A, member 2 | FDA approved drug targets Predicted intracellular proteins Predicted membrane proteins
| | | | | Mixed |
OXTR | Oxytocin receptor | FDA approved drug targets G-protein coupled receptors Predicted intracellular proteins Predicted membrane proteins
| | | | | Tissue enhanced |
PDGFRB | Platelet-derived growth factor receptor, beta polypeptide | Cancer-related genes CD markers Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins Predicted secreted proteins RAS pathway related proteins
| | | | | Mixed |
PGF | Placental growth factor | Cancer-related genes Candidate cardiovascular disease genes FDA approved drug targets Plasma proteins Predicted secreted proteins RAS pathway related proteins
| | | | | Tissue enhanced |
PLAT | Plasminogen activator, tissue | Cancer-related genes Candidate cardiovascular disease genes Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted secreted proteins
| | | | | Mixed |
PLAU | Plasminogen activator, urokinase | Cancer-related genes Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted secreted proteins
| | | | | Expressed in all |
PLAUR | Plasminogen activator, urokinase receptor | Cancer-related genes CD markers FDA approved drug targets Predicted intracellular proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
PLG | Plasminogen | Cancer-related genes Candidate cardiovascular disease genes Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted secreted proteins
| | | | | Tissue enriched |
PLIN3 | Perilipin 3 | FDA approved drug targets Plasma proteins Predicted intracellular proteins
| | | | | Expressed in all |
PTH2R | Parathyroid hormone 2 receptor | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| | | | | Tissue enhanced |
RAMP1 | Receptor (G protein-coupled) activity modifying protein 1 | FDA approved drug targets Predicted membrane proteins
| | | | | Mixed |
SCTR | Secretin receptor | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins Transporters
| | | | | Group enriched |
SERPINB2 | Serpin peptidase inhibitor, clade B (ovalbumin), member 2 | Cancer-related genes FDA approved drug targets Plasma proteins Predicted secreted proteins
| | | | | Tissue enhanced |
SERPINC1 | Serpin peptidase inhibitor, clade C (antithrombin), member 1 | Candidate cardiovascular disease genes Disease related genes FDA approved drug targets Plasma proteins Predicted secreted proteins
| | | | | Tissue enriched |
SERPIND1 | Serpin peptidase inhibitor, clade D (heparin cofactor), member 1 | Candidate cardiovascular disease genes Disease related genes FDA approved drug targets Plasma proteins Predicted secreted proteins
| | | | | Tissue enriched |
SERPINE1 | Serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1 | Cancer-related genes Candidate cardiovascular disease genes Disease related genes FDA approved drug targets Plasma proteins Predicted secreted proteins
| | | | | Tissue enhanced |
SNAP25 | Synaptosomal-associated protein, 25kDa | FDA approved drug targets Predicted intracellular proteins Transporters
| | | | | Tissue enriched |
SYT2 | Synaptotagmin II | FDA approved drug targets Predicted membrane proteins
| | | | | Tissue enhanced |
TNFRSF8 | Tumor necrosis factor receptor superfamily, member 8 | Cancer-related genes CD markers FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins
| | | | | Mixed |
TNFSF11 | Tumor necrosis factor (ligand) superfamily, member 11 | Cancer-related genes CD markers Disease related genes FDA approved drug targets Predicted intracellular proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
TNFSF13B | Tumor necrosis factor (ligand) superfamily, member 13b | Cancer-related genes CD markers FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins
| | | | | Mixed |
TSHR | Thyroid stimulating hormone receptor | Cancer-related genes Disease related genes FDA approved drug targets G-protein coupled receptors Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enriched |
VAMP1 | Vesicle-associated membrane protein 1 (synaptobrevin 1) | FDA approved drug targets Mitochondrial proteins Predicted membrane proteins Transporters
| | | | | Expressed in all |
VEGFA | Vascular endothelial growth factor A | Cancer-related genes Candidate cardiovascular disease genes Disease related genes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted secreted proteins RAS pathway related proteins
| | | | | Expressed in all |
VEGFB | Vascular endothelial growth factor B | Cancer-related genes FDA approved drug targets Predicted intracellular proteins Predicted secreted proteins RAS pathway related proteins
| | | | | Expressed in all |
VWF | Von Willebrand factor | Cancer-related genes Candidate cardiovascular disease genes Disease related genes FDA approved drug targets Plasma proteins Predicted secreted proteins
| | | | | Mixed |